Edition:
United States

Eiger BioPharmaceuticals Inc (EIGR.OQ)

EIGR.OQ on NASDAQ Stock Exchange Global Market

8.45USD
23 Feb 2018
Change (% chg)

$-0.05 (-0.59%)
Prev Close
$8.50
Open
$8.55
Day's High
$8.65
Day's Low
$8.40
Volume
12,707
Avg. Vol
35,504
52-wk High
$16.15
52-wk Low
$6.15

Chart for

About

Eiger BioPharmaceuticals, Inc., formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe... (more)

Overall

Beta: 1.78
Market Cap(Mil.): $88.86
Shares Outstanding(Mil.): 10.52
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 195.87 16.59
EPS (TTM): -- -- --
ROI: -- -0.71 35.07
ROE: -- -3.37 17.79

Eiger to abandon blood pressure drug after trial failure

Eiger BioPharmaceuticals Inc said on Tuesday it would stop development of its blood pressure drug after it failed in a mid-stage study, sending its shares plunging about 46 percent.

Jan 16 2018

UPDATE 2-Eiger to abandon blood pressure drug after trial failure

* Shares slump about 46 pct in morning trading (Adds details on company's pipeline, CEO's and analyst comment, background on PAH; updates share movement)

Jan 16 2018

Eiger BioPharma abandons blood pressure drug after failed study

Jan 16 Eiger BioPharmaceuticals Inc said on Tuesday it would stop testing its drug ubenimex for the treatment of pulmonary arterial hypertension, a type of high blood pressure, after the drug failed to meet the main goal in a mid-stage study.

Jan 16 2018

BRIEF-Eiger Biopharma Says Phase 2 Liberty Study In Pulmonary Arterial Hypertension Did Not Meet Main Goal

* EIGER BIOPHARMACEUTICALS ANNOUNCES PHASE 2 LIBERTY STUDY IN PULMONARY ARTERIAL HYPERTENSION DID NOT MEET PRIMARY ENDPOINT

Jan 16 2018

BRIEF-Eiger Biopharma Files For Mixed Shelf Of Up To $125 Mln

* EIGER BIOPHARMACEUTICALS INC FILES FOR MIXED SHELF OF UP TO $125 MILLION - SEC FILING Source text: (http://bit.ly/2nUkpvR) Further company coverage:

Dec 11 2017

BRIEF-‍Prosight Management reports a 6.9 percent passive stake in Eiger Biopharmaceuticals​

* ‍Prosight Management reports a 6.9 percent passive stake in Eiger Biopharmaceuticals​ as of Oct 31 - SEC filing Source text: (http://bit.ly/2mbmToK) Further company coverage:

Nov 09 2017

BRIEF-Eiger Biopharmaceuticals reports Q3 loss per share $1.10

* Eiger Biopharmaceuticals reports third quarter 2017 financial results

Nov 09 2017

BRIEF-Eiger Biopharmaceuticals closes public offering

* Eiger Biopharmaceuticals announces closing of public offering of common stock and exercise in full of underwriter's option to purchase additional shares Source text for Eikon: Further company coverage:

Oct 31 2017

BRIEF-EIGER BIOPHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

* EIGER BIOPHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

Oct 27 2017

BRIEF-Eiger BioPharmaceuticals announces proposed public offering of common stock

* Eiger BioPharmaceuticals announces proposed public offering of common stock

Oct 26 2017

Earnings vs. Estimates